Summary & Overview
HCPCS J9022: Atezolizumab Injection, 10 mg
HCPCS Level II code J9022 denotes a 10 mg unit of atezolizumab administered by injection, a monoclonal antibody used in oncology as an immune checkpoint inhibitor. Nationally, biologic oncology injectables like atezolizumab carry clinical and financial significance due to high per-dose costs, site-of-service variability, and evolving coverage policies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for use of atezolizumab, typical sites of service, and the billing implications of unit-based HCPCS reporting. The publication summarizes payer coverage patterns and benchmarks where available, highlights policy updates affecting reimbursement and billing practice, and outlines coding considerations for administering clinicians and billing staff.
This resource helps billing managers, oncology practice leaders, and health plan analysts understand how HCPCS Level II code J9022 is used in claims, what benchmarks and policy trends are relevant, and which operational factors — such as infusion setting and dosing units — commonly influence billing and reimbursement.
Billing Code Overview
HCPCS Level II code J9022 represents an injection of atezolizumab, 10 mg. This code describes a parenteral administration of the monoclonal antibody atezolizumab, typically used in oncology for immune checkpoint inhibition.
Service Type: Injection / Intravenous infusion
Typical Site of Service: Hospital outpatient department, physician office, or infusion center
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, or service line.
Clinical & Coding Specifications
Clinical Context
A 67-year-old patient with metastatic urothelial carcinoma presents to an outpatient infusion center for systemic immunotherapy. The oncology team has ordered atezolizumab for PD-L1–expressing tumor based on prior progression after platinum-based chemotherapy. The medication is supplied as vials and billed per 10 mg unit using J9022. The typical workflow includes outpatient check-in, verification of orders and eligibility, pre-infusion nursing assessment (vital signs, review of prior laboratory results including hepatic and renal panels), administration of pre-medication if clinically indicated, intravenous infusion of the calculated atezolizumab dose by oncology infusion nursing under physician/advanced practice provider oversight, monitoring for infusion-related or immune-mediated adverse events for the recommended observation period, documentation of lot number, units administered, start/stop times, and any reactions, and preparation of a claim with appropriate modifier(s) to indicate professional component, medically necessary circumstances, or billing exceptions as required by the payer.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug wastage discarded | Use when a portion of a single-use vial dose is discarded and wastage billing rules apply. |